Optimi Health Launches Ibogaine Initiative as U.S. Executive Order Signals Pathway for Psychedelic Drug Products

April 20, 2026 at 09:58 AM EDT

ⓘ This article is third-party content and does not represent the views of this site. We make no guarantees regarding its accuracy or completeness.

2149611199 1 1 Optimi Health Launches Ibogaine Initiative as U.S. Executive Order Signals Pathway for Psychedelic Drug Products

The Company’s Health Canada-licensed GMP psychedelic manufacturing platform ready to serve emerging demand for ibogaine, a naturally occurring alkaloid under investigation for opioid use disorder, PTSD, and traumatic brain injury Vancouver, British Columbia–(April 20, 2026) – Optimi Health Corp. (CSE:OPTI) (OTCQX:OPTHF) (FSE: 8BN) (the “Company” or “Optimi“), a commercial-stage pharmaceutical manufacturer of regulated psychedelic drug … Continue reading

Report this content

If you believe this article contains misleading, harmful, or spam content, please let us know.

Report this article

Symbol	Price	Change (%)
AMZN	270.64	-3.36 (-1.23%)
AAPL	312.06	-0.45 (-0.14%)
AMD	516.10	-1.99 (-0.38%)
BAC	51.60	+51.59 (1031900.00%)
GOOG	376.43	-9.69 (-2.51%)
META	632.51	-2.78 (-0.44%)
MSFT	450.24	+23.25 (5.45%)
NVDA	211.14	+211.12 (986535.51%)
ORCL	225.78	+22.08 (10.84%)
TSLA	435.79	-6.31 (-1.43%)

Symbol

Price

Change (%)

AMZN

270.64

-3.36 (-1.23%)

AAPL

312.06

-0.45 (-0.14%)

AMD

516.10

-1.99 (-0.38%)

BAC

51.60

+51.59 (1031900.00%)

GOOG

376.43

-9.69 (-2.51%)

Optimi Health Launches Ibogaine Initiative as U.S. Executive Order Signals Pathway for Psychedelic Drug Products

More News

Recent Quotes